glucagon has been researched along with glucose, (beta-d)-isomer in 49 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (glucose, (beta-d)-isomer) | Trials (glucose, (beta-d)-isomer) | Recent Studies (post-2010) (glucose, (beta-d)-isomer) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 21,956 | 883 | 10,747 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.16) | 18.7374 |
| 1990's | 1 (2.04) | 18.2507 |
| 2000's | 6 (12.24) | 29.6817 |
| 2010's | 25 (51.02) | 24.3611 |
| 2020's | 13 (26.53) | 2.80 |
| Authors | Studies |
|---|---|
| Hynie, S; Klenerová, V; Wenke, M | 1 |
| Alfiero, R; Cocco, G; Padula, A; Rizzo, A; Strozzi, C; Tasini, MT; Urso, L | 1 |
| Eilen, SD; Shah, SV; Wallin, JD | 1 |
| Ikeda, M; Imura, H; Nakahara, H; Seino, S; Seino, Y; Takai, J; Usami, M | 1 |
| McCann, P; Meezan, E; Pillion, DJ; Wang, P; Yorks, J | 1 |
| Arakawa, K; Ishihara, T; Kitamura, K; Matsumoto, M; Nawano, M; Oku, A; Saito, A; Ueta, K | 1 |
| Alstrup, KK; Gregersen, S; Hermansen, K; Jeppesen, PB | 1 |
| Agger, A; Colombo, M; Gregersen, S; Hermansen, K; Jeppesen, PB; Jepsen, M; Kruhøffer, M; Orntoft, T; Rolfsen, SE; Xiao, J | 1 |
| Gregersen, S; Hermansen, K; Holst, JJ; Jeppesen, PB | 1 |
| Chen, L; Hermansen, K; Hong, J; Jeppesen, PB; Nordentoft, I | 1 |
| Donahue, EP; Fujimoto, Y; Shiota, M; Torres, TP | 1 |
| Abdul-Ghani, MA; Daniele, G; DeFronzo, RA; Eldor, R; Fiorentino, TV; Merovci, A; Norton, L; Perez, Z; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Condren, AB; Donahue, EP; Farmer, TD; Healey, EC; Kim, K; McCoy, GA; O'Brien, TP; Printz, RL; Shiota, M; Ueta, K | 1 |
| Abderrahmani, A; Beaucamps, C; Bonner, C; Delalleau, N; Deprez, B; Gmyr, V; Kerr-Conte, J; Malaisse, WJ; Moerman, E; Pattou, F; Popescu, I; Queniat, G; Sener, A; Staels, B; Thévenet, J | 1 |
| Sargent, J | 1 |
| Kibbey, RG | 1 |
| Hattersley, AT; Thorens, B | 1 |
| Astiarraga, B; Baldi, S; Bizzotto, R; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Pieber, TR | 1 |
| Naito, T; Okamoto, A; Sanada, H; Yokokawa, H | 1 |
| Ahlstedt, I; El Hachmane, MF; Göpel, SO; Pedersen, MG | 1 |
| Abdul-Ghani, M; Daniele, G; DeFronzo, RA; Eldor, R; Merovci, A; Norton, L; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Ceriello, A; Genovese, S; Gronda, E; Mannucci, E | 1 |
| Gilbert, JD; Goldenberg, RM; Perkins, BA; Verma, S; Zinman, B | 1 |
| Andersen, G; Falk, A; Fischer, A; Forst, T; Heise, T; Kapitza, C; Plum-Mörschel, L; Voswinkel, S; Weber, MM | 1 |
| Abdul-Ghani, M; Adams, J; Al Jobori, H; Cersosimo, E; Daniele, G; DeFronzo, RA; Triplitt, C | 1 |
| Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D | 1 |
| Dotta, F; Nigi, L; Rossi, C; Santini, E; Sebastiani, G; Solini, A | 1 |
| Chen, S; Davidson, JA; Holland, WL; Lee, Y; Li, J; McCorkle, SK; Roth, MG; Scherer, PE; Unger, RH; Wang, MY; Wang, ZV; Yu, X | 1 |
| Bjourson, AJ; Flatt, PR; Gault, VA; Millar, P; Moffett, RC; O'Kane, M; Parthsarathy, V; Pathak, N; Pathak, V | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Jakupović, L; Javor, E; Lucijanić, M; Lucijanić, T; Rahelić, D; Skelin, M | 1 |
| Giehm, L; Madsen, JK; Otzen, DE | 1 |
| Kakizaki, S; Kikuchi, O; Kitamura, T; Kobayashi, M; Kohno, D; Matsui, S; Sasaki, T; Suga, T; Takeuchi, K; Wada, E; Yamada, M; Yokota-Hashimoto, H | 1 |
| Adam, J; Ashcroft, FM; Asterholm, IW; Benrick, A; Briant, LJB; Chibalina, MV; Gribble, FM; Hamilton, A; Hastoy, B; Knudsen, JG; Ramracheya, R; Reimann, F; Rorsman, NJG; Rorsman, P; Salehi, A; Spiliotis, II; Tarasov, A; Vergari, E; Wu, Y; Zhang, Q | 1 |
| Abdel-Hamid, AAM; Firgany, AEL | 1 |
| Bonner, C; Bousquet, C; Coddeville, A; Daoudi, M; Delalleau, N; Gmyr, V; Hubert, T; Kerr-Conte, J; Martineau, Y; Moerman, E; Pasquetti, G; Pattou, F; Quenon, A; Saponaro, C; Staels, B; Thévenet, J; Vantyghem, MC | 1 |
| Acosta-Montalvo, A; Bonner, C; Cnop, M; Coddeville, A; Delalleau, N; Gmyr, V; Kerr-Conte, J; Moerman, E; Mühlemann, M; Pasquetti, G; Pattou, F; Piron, A; Saponaro, C; Staels, B; Thévenet, J | 1 |
| Astapova, II; Campbell, JE; Capozzi, ME; Coch, RW; D'Alessio, DA; Douros, JD; El, K; Encisco, SE; Finan, B; Herman, MA; Koech, J; Sloop, KW; Wait, JB | 1 |
| Flatt, PR; Irwin, N; Moffett, RC; Tanday, N | 1 |
| Bottino, R; Bouchi, Y; Calcutt, MW; Dai, C; Dean, ED; Greiner, DL; Hart, NJ; Jacobson, DA; McGuinness, OP; Poffenberger, G; Powers, AC; Shostak, A; Shultz, LD; Walker, JT | 1 |
| Cui, X; Feng, J; Gu, L; Hong, T; Lang, S; Le, Y; Liu, J; Wang, H; Wei, R; Wei, T; Yang, J; Yang, K | 1 |
| Antoine, N; Augustin, R; Bensellam, M; Broca, C; Brusa, D; Chae, H; Gatineau, E; Gilon, P; Gribble, FM; Herrera, PL; Khattab, F; Klein, H; Lai, BK; Mark, M; Mayoux, E; Piemonti, L; Pieper, M; Reimann, F; Rita, N; Ruiz, L; Singh, B; Stierstorfer, B; Wojtusciszyn, A | 1 |
| Holst, JJ; Hædersdal, S; Knop, FK; Lund, A; Maagensen, H; Nielsen-Hannerup, E; van Hall, G; Vilsbøll, T | 1 |
| Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Faerch, K; Holst, JJ; Jørgensen, ME; Karstoft, K; Persson, F; Quist, JS; Ried-Larsen, M; Torekov, SS; Vistisen, D; Wewer Albrechtsen, NJ | 1 |
| Deacon, CF; Holst, JJ; Kuhre, RE; Wewer Albrechtsen, NJ | 1 |
| Boeder, SC; Giovannetti, ER; Gregory, JM; Pettus, JH | 1 |
| Anno, M; Fujioka, Y; Imamura, T; Ito, Y; Izawa, S; Kato, M; Kitao, S; Matsumoto, K; Matsuzawa, K; Nakamura, R; Okura, H; Okura, T; Shoji, K; Taniguchi, SI; Ueta, E; Yamamoto, K | 1 |
| Adams, J; Agyin, C; Alatrach, M; Cersosimo, E; DeFronzo, RA; Gastaldelli, A; Lavryneko, O; Solis-Herrera, C; Triplitt, C | 1 |
| Birnie, E; Burggraaf, B; Castro Cabezas, M; de Herder, WW; Fernández Arroyo, S; Huisbrink, J; Mulder, MT; Pouw, NMC; Rensen, PCN; van de Geijn, GM; van der Zwan, EM; van Vark-van der Zee, LC | 1 |
6 review(s) available for glucagon and glucose, (beta-d)-isomer
| Article | Year |
|---|---|
[Old and new positive inotropic drugs: problems and controversies].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; Glucagon; Glucosides; Heart Failure; Histamine; Humans; Imidazoles; Inosine; Quinazolines; Xanthines | 1984 |
Glucagon and heart in type 2 diabetes: new perspectives.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucosides; Heart; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Myocardium; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus; Drug Therapy, Combination; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Incretins; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide | 2018 |
Do sodium-glucose co-transporter-2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucosides; Humans; Pharmaceutical Preparations; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
9 trial(s) available for glucagon and glucose, (beta-d)-isomer
| Article | Year |
|---|---|
Antihyperglycemic effects of stevioside in type 2 diabetic subjects.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Diterpenes; Diterpenes, Kaurane; Diuresis; Fatty Acids, Nonesterified; Female; Food; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Kinetics; Male; Middle Aged; Peptide Fragments; Placebos; Protein Precursors; Triglycerides | 2004 |
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucose; Glucose Clamp Technique; Glucosides; Humans; Hyperglycemia; Insulin; Male; Metformin; Middle Aged; Muscles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2014 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Lipolysis; Membrane Transport Modulators; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2016 |
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Calorimetry, Indirect; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Glucagon; Glucosides; Humans; Insulin; Insulin Resistance; Ketones; Lipid Metabolism; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2016 |
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Linagliptin; Male; Middle Aged; Postprandial Period; Proinsulin; Treatment Outcome | 2017 |
No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prediabetic State | 2021 |
SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Clamp Technique; Glucosides; Glycemic Control; Humans; Hypoglycemia; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Humans; Insulin; Insulin Resistance; Japan; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2022 |
Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Insulin; Lipid Metabolism; Male | 2022 |
34 other study(ies) available for glucagon and glucose, (beta-d)-isomer
| Article | Year |
|---|---|
Inhibitory effects of pentacaine and some related local anaesthetics on rat hepatic adenylate cyclase.
Topics: Adenylyl Cyclase Inhibitors; Anesthetics, Local; Animals; Carbamates; Colforsin; Glucagon; Glucosides; Guanylyl Imidodiphosphate; Liver; Piperidines; Rats; Structure-Activity Relationship | 1985 |
Chemiluminescence and superoxide anion production by leukocytes from diabetic patients.
Topics: Adult; Aged; Anions; Diabetes Mellitus; Glucagon; Humans; Kinetics; Luminescent Measurements; Middle Aged; Neutrophils; Opsonin Proteins; Oxygen; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 1983 |
Effect of cyclamate sodium, saccharin sodium and stevioside on arginine-induced insulin and glucagon secretion in the isolated perfused rat pancreas.
Topics: Animals; Arginine; Cyclamates; Diterpenes; Diterpenes, Kaurane; Glucagon; Glucosides; Glycosides; Insulin; Insulin Secretion; Male; Pancreas; Perfusion; Rats; Saccharin; Terpenes | 1980 |
Systemic absorption of insulin and glucagon applied topically to the eyes of rats and a diabetic dog.
Topics: Absorption; Administration, Topical; Animals; Blood Glucose; Detergents; Diabetes Mellitus; Dogs; Drug Carriers; Eye; Gastrointestinal Agents; Glucagon; Glucosides; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Nasal Mucosa; Ophthalmic Solutions; Rats; Rats, Sprague-Dawley | 1995 |
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095.
Topics: Animals; Blood Glucose; Carbonates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucagon; Glucose Tolerance Test; Glucosides; Glycosuria; Hypoglycemic Agents; Insulin; Kidney Glomerulus; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Obese; Microvilli; Monosaccharide Transport Proteins; Pancreas; Phenotype; Sodium-Glucose Transporter 1 | 2001 |
Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo: studies in the diabetic Goto-Kakizaki (GK) rats.
Topics: Animals; Area Under Curve; Diabetes Mellitus, Type 2; Disease Models, Animal; Diterpenes; Diterpenes, Kaurane; Glucagon; Glucose; Glucose Tolerance Test; Glucosides; Hyperglycemia; Hypoglycemic Agents; Injections, Intravenous; Insulin; Male; Phytotherapy; Plant Extracts; Rats; Rats, Inbred Strains; Rats, Wistar; Terpenes | 2002 |
Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki rat.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Cell Line; Diabetes Mellitus, Type 2; Diterpenes; Diterpenes, Kaurane; Fasting; Gene Expression Profiling; Glucagon; Glucose Tolerance Test; Glucosides; Hypoglycemic Agents; Insulin; Islets of Langerhans; Kinetics; Male; Rats; Rats, Wistar | 2003 |
Stevioside counteracts the alpha-cell hypersecretion caused by long-term palmitate exposure.
Topics: Acetyl-CoA Carboxylase; Animals; Carnitine O-Palmitoyltransferase; Cell Line, Tumor; Diterpenes, Kaurane; Drug Interactions; Gene Expression; Glucagon; Glucagon-Secreting Cells; Glucosides; Hypoglycemic Agents; Mice; Mice, Transgenic; Palmitates; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Secretory Rate; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1 | 2006 |
Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats.
Topics: Animals; Blood Glucose; Carbonates; Carrier Proteins; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Glucokinase; Glucose; Glucose-6-Phosphatase; Glucosides; Glycogen; Glycogen Synthase; Hyperglycemia; Insulin; Liver; Liver Glycogen; Male; Muscle, Skeletal; Phosphorylases; Rats; Rats, Zucker | 2006 |
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
Topics: Animals; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucokinase; Glucose; Glucose Clamp Technique; Glucosides; Hyperglycemia; Hyperinsulinism; Immunohistochemistry; Liver; Male; Obesity; Organ Size; Oxygen Consumption; Rats; Rats, Zucker; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Topics: Administration, Oral; Adult; Animals; Benzhydryl Compounds; Blood Glucose; Cell Separation; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation; Gene Silencing; Glucagon; Glucagon-Secreting Cells; Gluconeogenesis; Glucosides; Hepatocyte Nuclear Factor 4; Humans; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; RNA, Small Interfering; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 | 2015 |
Therapy: SGLT2 inhibitor dapagliflozin promotes glucagon secretion in α islet cells.
Topics: Animals; Benzhydryl Compounds; Female; Gene Expression Regulation; Glucagon; Glucagon-Secreting Cells; Glucosides; Humans; Male; Sodium-Glucose Transporter 2 | 2015 |
SGLT-2 inhibition and glucagon: Cause for alarm?
Topics: Animals; Benzhydryl Compounds; Female; Gene Expression Regulation; Glucagon; Glucagon-Secreting Cells; Glucosides; Humans; Male; Sodium-Glucose Transporter 2 | 2015 |
Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Glucosides; Humans; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.
Topics: Adipocytes; Adiponectin; Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; C-Reactive Protein; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1 | 2016 |
Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells.
Topics: Animals; Benzhydryl Compounds; Cells, Cultured; Electric Stimulation; Glucagon; Glucagon-Secreting Cells; Glucose; Glucosides; Humans; Mice; Models, Theoretical; Sodium-Glucose Transporter 2 | 2016 |
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Ketones; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glucosides; Growth Hormone-Secreting Pituitary Adenoma; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Severity of Illness Index; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
Topics: Animals; Benzhydryl Compounds; Cell Line; Cells, Cultured; Gene Silencing; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Glucosides; Humans; Mice; Signal Processing, Computer-Assisted; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Somatostatin | 2017 |
Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-Regulation; Glucagon; Glucagon-Secreting Cells; Glucose; Glucosides; Hypoglycemic Agents; Kidney Tubules, Proximal; Male; Mice; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rodentia; Signal Transduction; Sodium-Glucose Transporter 2 | 2017 |
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Interleukin-6; Liraglutide; Male; Mice; Neurons; Neuroprotective Agents | 2017 |
The Use of Surfactants to Solubilise a Glucagon Analogue.
Topics: Glucagon; Glucosides; Glycolipids; Lipopeptides; Oleic Acids; Peptides, Cyclic; Polysorbates; Protein Aggregates; Protein Conformation, alpha-Helical; Sodium Dodecyl Sulfate; Solubility; Surface-Active Agents | 2018 |
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus; Diet, High-Fat; Disease Models, Animal; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Glucosides; Glycosuria; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus; Female; Glucagon; Glucagon-Secreting Cells; Glucosides; Humans; Hypoglycemia; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor, Insulin; Receptors, Somatostatin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Somatostatin | 2019 |
Modulatory effect of empagliflozin on cellular parameters of endocrine pancreas in experimental pre-diabetes.
Topics: Animals; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Caspase 3; Cell Proliferation; Cytokines; Diabetes Mellitus, Experimental; Glucagon; Glucagon-Secreting Cells; Glucose Tolerance Test; Glucosides; Homeostasis; Immunohistochemistry; Insulin-Secreting Cells; Islets of Langerhans; Male; Prediabetic State; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Glucagon; Glucosides; Humans; Liraglutide; Male; Mice; Somatostatin | 2019 |
Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets.
Topics: Antibodies; Benzhydryl Compounds; Blood Glucose; Databases, Nucleic Acid; Glucagon; Glucose; Glucosides; HEK293 Cells; Humans; Islets of Langerhans; RNA, Small Interfering; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Epinephrine; Food Deprivation; Gene Expression Regulation; Glucagon; Glucosides; Insulin; Lipolysis; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Cell Transdifferentiation; Diabetes Mellitus, Experimental; Diet, High-Fat; Energy Intake; Glucagon; Glucagon-Secreting Cells; Glucosides; Homeodomain Proteins; Hydrocortisone; Insulin; Insulin Resistance; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice, Transgenic; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Trans-Activators | 2020 |
Dapagliflozin Does Not Directly Affect Human α or β Cells.
Topics: Adolescent; Adult; Animals; Benzhydryl Compounds; Cells, Cultured; Female; Glucagon; Glucagon-Secreting Cells; Glucosides; Heterografts; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Mice, Inbred NOD; Mice, Transgenic; Middle Aged; Signal Transduction; Species Specificity; Young Adult | 2020 |
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Endocrine Cells; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Glucose; Glucosides; Insulin; Insulin-Secreting Cells; Male; Mice; Proprotein Convertase 1; Regeneration; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Glucosides; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Mice; Pancreas; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
Topics: Benzhydryl Compounds; Biphenyl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Energy Metabolism; Gastric Emptying; Glucagon; Glucosides; Glycerol; Half-Life; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2022 |